Newswise — April 5, 2016, New York, NY - Sir David Lane, Ludwig Cancer Research’s scientific director, was elected today as a fellow of the American Association for Cancer Research (AACR). Election as a fellow is the most prestigious honor bestowed by AACR and recognizes those researchers who have made exceptional contributions to the understanding and treatment of cancer.

Professor Lane is most well known for his landmark discovery of the p53 protein, which functions as a vitally important tumor suppressor involved in preventing cancer. The p53 is mutated or at fault in 50 percent of human cancers. He continues to advance pioneering research with a focus on controlling p53 and identifying targets for developing new cancer therapies that could restore normal function.

David Lane joins 11 of his esteemed Ludwig colleagues who were elected as AACR fellows in previous years. He will be formally recognized during a ceremony at the AACR Annual Meeting on Friday, April 15, 2016.

About Ludwig Cancer ResearchLudwig Cancer Research is an international collaborative network of acclaimed scientists that has pioneered cancer discoveries for more than 40 years. Ludwig combines basic research with the ability to translate its discoveries and conduct clinical trials to accelerate the development of new cancer diagnostics and therapies. Since 1971, Ludwig has invested nearly $2.7 billion in life-changing science through the not-for-profit Ludwig Institute for Cancer Research and the six U.S.-based Ludwig Centers. To learn more, visit

For further information please contact Rachel Steinhardt, [email protected] or +1-212-450-1582.